Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.

Automated summary

Chronic kidney disease (CKD) is a disabling disorder with high incidence and prevalence in cancer survivors due to kidney damage caused by cancer and its treatment. Special attention should be given to the treatment of CKD and its complications in cancer survivors, considering their comorbidities, risk of cancer recurrence, limited physical function, and life expectancy. Shared decision-making should be adopted when selecting renal replacement therapies with sufficient information and evidence.